» Articles » PMID: 21631316

Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers

Abstract

Background: The Extension for Community Healthcare Outcomes (ECHO) model was developed to improve access to care for underserved populations with complex health problems such as hepatitis C virus (HCV) infection. With the use of video-conferencing technology, the ECHO program trains primary care providers to treat complex diseases.

Methods: We conducted a prospective cohort study comparing treatment for HCV infection at the University of New Mexico (UNM) HCV clinic with treatment by primary care clinicians at 21 ECHO sites in rural areas and prisons in New Mexico. A total of 407 patients with chronic HCV infection who had received no previous treatment for the infection were enrolled. The primary end point was a sustained virologic response.

Results: A total of 57.5% of the patients treated at the UNM HCV clinic (84 of 146 patients) and 58.2% of those treated at ECHO sites (152 of 261 patients) had a sustained viral response (difference in rates between sites, 0.7 percentage points; 95% confidence interval, -9.2 to 10.7; P=0.89). Among patients with HCV genotype 1 infection, the rate of sustained viral response was 45.8% (38 of 83 patients) at the UNM HCV clinic and 49.7% (73 of 147 patients) at ECHO sites (P=0.57). Serious adverse events occurred in 13.7% of the patients at the UNM HCV clinic and in 6.9% of the patients at ECHO sites.

Conclusions: The results of this study show that the ECHO model is an effective way to treat HCV infection in underserved communities. Implementation of this model would allow other states and nations to treat a greater number of patients infected with HCV than they are currently able to treat. (Funded by the Agency for Healthcare Research and Quality and others.).

Citing Articles

Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial.

Jillella A, Lee S, Altman J, Luger S, Tallman M, Foran J JAMA Oncol. 2025; .

PMID: 40014329 PMC: 11869096. DOI: 10.1001/jamaoncol.2024.7033.


Peer-assisted telemedicine hepatitis-C treatment for people who use drugs in rural communities: a mixed methods study.

Hoffman K, Leichtling G, Shin S, Seaman A, Gailey T, Spencer H Addict Sci Clin Pract. 2025; 20(1):10.

PMID: 39923115 PMC: 11806898. DOI: 10.1186/s13722-025-00541-6.


Project ECHO dermatology in the deep south: a comprehensive SWOT assessment.

Reeves C, Islam R, Mockbee C, Helms S, Huynh T, Hughes L Arch Dermatol Res. 2025; 317(1):343.

PMID: 39912985 DOI: 10.1007/s00403-025-03874-z.


WHO public health laboratories webinar series - an online platform to disseminate testing recommendations and best practices during health emergencies.

Barnadas C, Stevens L, Milhano N, Barbosa de Lima A, Struminger B, Burke L Front Public Health. 2025; 12:1462756.

PMID: 39882110 PMC: 11775005. DOI: 10.3389/fpubh.2024.1462756.


Challenges of Engaging Primary Care Providers in Specialized Telementoring Education About Sickle Cell Disease for Sickle Cell Specialists: Results from the Sickle Cell Disease Training and Mentoring Program for Primary Care Providers (STAMP)....

Shook L, House B, Farrell C, Stewart R, Lanzkron S, King A AJPM Focus. 2025; 4(1):100304.

PMID: 39866157 PMC: 11758125. DOI: 10.1016/j.focus.2024.100304.


References
1.
Rodriguez-Torres M, Jeffers L, Sheikh M, Rossaro L, Ankoma-Sey V, Hamzeh F . Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009; 360(3):257-67. DOI: 10.1056/NEJMoa0805062. View

2.
Kanwal F, Hoang T, Spiegel B, Eisen S, Dominitz J, Gifford A . Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology. 2007; 46(6):1741-9. DOI: 10.1002/hep.21927. View

3.
Arora S, Geppert C, Kalishman S, Dion D, Pullara F, Bjeletich B . Academic health center management of chronic diseases through knowledge networks: Project ECHO. Acad Med. 2007; 82(2):154-60. PMC: 3855463. DOI: 10.1097/ACM.0b013e31802d8f68. View

4.
Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. DOI: 10.1016/s0140-6736(01)06102-5. View

5.
Shim M, Khaykis I, Park J, Bini E . Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology. 2005; 42(3):688-95. DOI: 10.1002/hep.20830. View